Login
$IRLA
$37.36 -$2.44 (6.13%) Live

$IRLA SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 SCHEDULE 13G
13 Nov 2026 8-K: Results of Operations and Financial Condition

Name changed from Quince Therapeutics, Inc. to IRulya Therapeutics Inc.; common stock began trading on the Nasdaq Capital Market under the ticker “IRLA” on October 12, 2026

13 Nov 2026 10-Q
12 Nov 2026 Form 4: Wise John Drayton, Director

Granted 17,000 Director Stock Option (Right to Buy)

12 Nov 2026 Form 4: Valentine James Elwood, Director

Granted 17,000 Director Stock Option (Right to Buy)

12 Nov 2026 Form 4: Patterson Leone D, Director

Granted 17,000 Director Stock Option (Right to Buy)

12 Nov 2026 Form 4: Bonuccelli Catherine M., Director

Granted 17,000 Director Stock Option (Right to Buy)

12 Nov 2026 Form 4: Militello John, Chief Financial Officer

Received 80,000 shares as a grant or award

05 Nov 2026 144
21 Oct 2026 144
19 Oct 2026 Form 3: Bonuccelli Catherine M., Director

No securities owned

19 Oct 2026 Form 3: Valentine James Elwood, Director

No securities owned

19 Oct 2026 Form 3: Wise John Drayton, Director

No securities owned

19 Oct 2026 Form 3: Militello John, Chief Financial Officer

No securities owned

19 Oct 2026 Form 3: Fandrick Keith R., Chief Operating Officer
19 Oct 2026 Form 3: Patterson Leone D, Director

No securities owned

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support